Shoreline Biosciences, Inc. Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Shoreline Biosciences is a private biotechnology company based in La Jolla, California, focused on developing cellular immunotherapies derived from induced pluripotent stem cells. Its approach combines differentiating iPSCs into immune cells with genetic modulation of the IL-15/CISH axis to enhance the persistence and metabolic fitness of engineered natural killer cells, with the aim of improving anti-cancer activity. The company also develops macrophage-based therapies derived from the same iPSC platform. In the biotechnology research arena, Shoreline pursues collaborations with pharma and research organizations to advance iPSC-derived immune cell therapies for cancer and autoimmune disorders. A 2023 collaboration with Editas Medicine to license Editas's SLEEK and AsCas12a gene-editing technologies and acquire preclinical iNK programs is noted. The company is based in La Jolla, California, and operates with a small team.